Retinoid-induced hyperlipidemia and the risk of atherosclerosis

Retinoids and Carotenoids in Dermatology

Volumn , Issue , 2007, Pages 249-259

  Vahlquist, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960980845     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (24)

1. Walldius G, Junger I. The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and target for lipid-lowering therapy-a review of the evidence. J Intern Med 2006; 259: 493-519.
2. Vahlquist C, Michaelsson G, Vahlquist A, Vessby B. A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins. Br f Dermatol 1985; 112: 69-72.
3. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142: 1016-1022.
4. Lowe NJ, David M. Retinoid toxicity. In: Lowe NJ, Marks R, eds. Retinoids: A Clinician’s Guide. London: Martin Dunitz, 1998: 149-165.
5. McCarter TM, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992; 87: 1855-1858.
6. Gordon T, Castellli WP, Hjortland MC. Predicting coronary heart disease in middleaged and older persons; the Framingham study. JAMA 1977; 238: 497.
7. Staels B. Regulation of lipid and lipoprotein metabolism by retinoids. J Am Acad Dermatol 2001; 45: S158-S167.
8. Gustafsson S, Vahlquist C, Sjöblom L, et al. Metabolism of very low density lipoproteins in rats with isotretinoin (13-cis retinoic acid)-induced. J Lipid Research 1990; 31: 183-190.
9. Vahlquist C, Lithell H, Michaelsson G, et al. Plasma fat elimination, tissue lipoprotein lipase activity and plasma fatty acid composition during sequential treatment with etretinate and isotretinoin. Acta Derm Venereol 1987; 67: 139-144.
10. Vu-Dac N, Gervois P, Torra I P, et al. Retinoids increase human Apo C-III Expression at the transcriptional level via the retinoid X receptor. J Clin Invest 1998; 102: 625-632.
11. Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med 2002; 136: 582-589.
12. Standeven AM, Beard RL, Johnson AT, et al. Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic acid receptors. Fund Appl Toxicol 1996; 33: 264-271.
13. Davies PJA, Berry SA, Shipley GL, et al. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Molecul Pharmacol 2001; 59(2): 170-176.
14. Duriez P, Fruchart JC. Post-statin approaches to hyperlipidemia. Exp Opin Invest Drugs 1998; 7: 1997-2009.
15. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for the treatment of refractory advanced stage cutaneous T cell lymphoma: multinational phase II III trial results. J Clin Oncol 2000; 19: 2456-2471.
16. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340: 1075-1079.
17. Ashley JM, Lowe NJ, Borok ME, Alfin-Slater RB. Fish oil supplementation results in decreased hypertriglyceridemia in patients with psoriasis undergoing etretinate or acitretin therapy. J Am Acad Dermatol 1988; 19: 76-82.
18. Vahlquist C, Olsson AG, Lindholm A, Vahlquist A. Effects of Gemfibrozil (Lopid®) on hyperlipidemia in acitretin-treated patients. Acta Derm Venereol 1995; 75: 377-380.
19. Talpur R, WS, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Dermatol 2002; 47: 672-684.
20. Streb JW, Miano JM. Retinoids: pleiotropic agents of therapy for vascular diseases? Curr Drug Targets-Cardiovascular & Haemalolgical Disorders 2003; 3: 31-57.
21. Barbui T, Finazzi G, Falanga A. The imapct of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. J Am Soc Hematol 1988; 91: 3093-3102.
22. Falanga A, Toma S, Marchetti M, et al. Effects of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer. Am J Hematol 2002; 70: 9-15.
23. van Giezen JJJ, Boon GIA, Jansen JWC, Bouma BN. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis. Thrombos Haemostas 1993; 69: 381-386.
24. Bäck O, Nilsson TK. Retinoids and fibrinolysis. Acta Derm Venereol 1995; 75: 290-292.